Anti IL1RAP/CD3 bispecific antibodies have demonstrated a high degree of specificity and IL1RAP targeting therapies are now going into first-in-human clinical trials (NCT02842320) in leukemias [78]. The gene discussed is IL1RAP; the disease is leukemia.